DEF: Quanterix Seeks Board Declassification, Addresses Governance

Quanterix Corporation will hold its 2025 annual meeting to vote on board declassification, executive compensation, and auditor ratification, following recent board changes and financial restatements.

Summary

• Quanterix Corporation will hold its 2025 annual meeting virtually on September 23, 2025, to vote on six key proposals.
• Proposals include the election of three director nominees, an advisory vote on executive compensation, and the ratification of KPMG LLP as the independent auditor for fiscal year 2025.
• Significant corporate governance changes are proposed, including a phased-in declassification of the Board of Directors, aiming for all directors to be elected annually by the 2028 annual meeting.
• The company also seeks to eliminate supermajority stockholder vote requirements for amending certain Charter provisions and the Bylaws, reducing them to a majority of outstanding shares.
• These governance changes follow a cooperation agreement with Kent Lake Partners LP, which also includes the appointment of a new independent director by December 1, 2025.
• The company reported 2024 revenues of $137.4 million and a net loss of $38.5 million.
• Executive compensation for 2024 included a base salary of $650,000 and a cash incentive bonus of $585,000 for CEO Masoud Toloue, and a base salary of $446,160 and a cash incentive bonus of $255,784 for CFO Vandana Sriram.
• The Compensation Committee adjusted the corporate performance factor for the 2024 annual cash incentive bonus to 0.9x, citing 12% revenue growth that outperformed industry peers, despite initial metric calculations yielding 0.75x.
• The company recently dismissed Ernst & Young LLP and appointed KPMG LLP as its independent auditor, following EY's adverse opinions on internal controls for 2023 and 2024 due to material weaknesses, including an inventory valuation error that led to financial restatements.

Sentiment

Score: 4

Explanation: While the company is proactively addressing corporate governance and showed strong revenue growth relative to peers, the persistent net losses, significant decline in TSR, and ongoing material weaknesses in internal controls, coupled with a recent financial restatement, indicate underlying operational and financial reporting challenges. The discretionary adjustment of executive bonuses also raises questions about strict performance alignment.

Positives

• Proposed corporate governance enhancements, including board declassification and elimination of supermajority voting requirements, align with modern best practices and increase board accountability.
• The company achieved 12% revenue growth in 2024, reaching $137.4 million, which outperformed the median 2024 revenue growth of its 2025 proxy peer group (2%) and most life sciences tools and services peers.
• The Compensation Committee's adjustment of the corporate performance factor to 0.9x for executive bonuses reflects recognition of strong revenue growth relative to peers in a capital-constrained environment.
• Remediation of the Property and Equipment material weakness by December 31, 2024, indicates progress in addressing internal control deficiencies.
• The company maintains strong corporate governance practices, including independent Chair and CEO roles, fully independent Audit, Compensation, and Nominating and Governance Committees, and stock ownership guidelines for executives and directors.

Negatives

• The company reported a net loss of $38.5 million in 2024, an increase from the restated net loss of $28.4 million in 2023.
• The company continues to have material weaknesses in internal control over financial reporting, specifically related to inventory valuation and, as of December 31, 2024, an additional material weakness in accounting for Accelerator Laboratory revenue.
• An error related to the capitalization of labor and overhead costs in inventory balances led to a restatement of financial statements for multiple periods (2022, 2023, Q1/Q2 2024).
• The initial calculation of the 2024 corporate performance factor for executive bonuses was 0.75x, based on revenue, non-GAAP gross margin, cash usage, and strategic objectives, which was then adjusted upwards to 0.9x by the Compensation Committee.
• Total Shareholder Return (TSR) decreased significantly from $115.70 in 2023 to $44.99 in 2024.
• The exercise prices of all outstanding stock options held by named executive officers as of December 31, 2024, were higher than the closing stock price of $10.63, indicating these options were out-of-the-money.

Risks

• Ongoing material weaknesses in internal control over financial reporting, particularly concerning inventory valuation and Accelerator Laboratory revenue, pose a risk to the accuracy and reliability of financial reporting.
• The recent restatement of financial statements due to an inventory capitalization error highlights the risk of further accounting errors and the associated costs and reputational damage.
• Persistent material weaknesses and financial restatements could lead to increased scrutiny from the SEC and other regulatory bodies.
• Despite proposed governance improvements, the company's financial performance (net losses, declining TSR) and internal control issues could lead to continued shareholder dissatisfaction.
• The Compensation Committee's discretionary adjustment of the corporate performance factor for executive bonuses, despite initial metric calculations yielding a lower result, could be perceived as a misalignment with strict performance-based compensation.
• The cooperation agreement with Kent Lake Partners LP includes 'no litigation provisions,' suggesting potential for past or future shareholder activism or disputes.
• Forward-looking statements are subject to risks and uncertainties that could cause actual events to differ materially, including future costs of solicitation, record or meeting dates, compensation arrangements, board composition, and company strategy.

Future Outlook

The company's forward-looking statements relate to future costs of solicitation, record or meeting dates, compensation arrangements or structure, the composition of the Board, future stockholder engagement, and the company's strategy. The company undertakes no obligation to revise any forward-looking statement to reflect subsequent events or circumstances, except as required by applicable law.

Management Comments

• Our Board of Directors recommends that you vote in accordance with its recommendation on each of the proposals using the enclosed proxy card.
• We hope you will be able to attend the Annual Meeting virtually. Whether or not you plan to attend the Annual Meeting, we hope you will vote promptly.
• Our compensation philosophy is designed to align each executive's compensation with Quanterix's short-term and long-term performance and to provide the compensation and incentives needed to attract, motivate and retain key executives who are crucial to our long-term success.
• The Compensation Committee and our Board of Directors believe that these policies and procedures are effective in implementing our compensation philosophy and in achieving its goals.
• Following a review of our compensation policies and practices, our Compensation Committee believes that risks arising from those policies and practices are not reasonably likely to have a material adverse effect on the Company.

Industry Context

The company operates in the life sciences tools and diagnostics industry. Its 12% revenue growth in 2024 significantly outperformed the median 2% revenue growth of its 2025 proxy peer group and most other companies in the life sciences tools and services segment, which generally experienced flat to declining growth rates. This suggests the company is gaining market share or benefiting from specific product cycles within a challenging or stagnant broader industry environment. The ongoing focus on corporate governance improvements, including board declassification, reflects a broader trend in the industry and public markets towards increased shareholder rights and board accountability.

Comparison to Industry Standards

• The company's 12% revenue growth in 2024 outperformed the median 2% revenue growth of its 2025 proxy peer group, which includes companies like Adaptive Biotechnologies Corporation, Pacific Biosciences of California, Inc., and Veracyte, Inc.
• The company's revenue growth also outperformed all but one of its 2025 proxy peers in the life sciences tools and services segment.
• Revenue growth was superior to that of certain larger companies in the life sciences tools and services segment, which had growth rates that were predominantly flat to declining.
• The company's proposed board declassification and elimination of supermajority voting align with evolving corporate governance best practices increasingly adopted by public companies to enhance shareholder rights and board accountability, moving away from structures that can entrench management.
• The company's pay ratio of 1:49 (CEO to median employee) is within the typical range for publicly traded companies, though direct comparisons require understanding of specific methodologies.
• The company's continued material weaknesses in internal controls, particularly after a financial restatement, fall below industry best practices for financial reporting integrity and operational efficiency.

Management Changes

Corporate Governance

Related Party Transactions

• License agreement with Tufts University for core SIMOA technology, where Dr. David R. Walt (director, founding scientist) receives a portion of royalties and license payments. Royalty expense of approximately $2.1 million in 2024.
• License agreement with Harvard University for immunoassay technology developed by Dr. Walt, where Dr. Walt receives a portion of payments. No royalty expense in 2024.
• Sales of products and services to laboratories affiliated with Harvard and Brigham and Women's Hospital overseen by Dr. Walt, generating approximately $2.2 million in revenue in 2024.

Stakeholder Impact

• Shareholders: Potential for increased influence over corporate governance through board declassification and reduced supermajority voting requirements. However, ongoing financial losses and internal control issues may negatively impact shareholder value. The cooperation agreement with Kent Lake Partners LP suggests active shareholder engagement and potential for influence.
• Employees: Executive compensation structure aims to attract and retain talent. The general benefit program is broad-based. The material weaknesses in internal controls could indicate operational inefficiencies that might indirectly affect employees.
• Customers: Sales of products and services to laboratories affiliated with Harvard and Brigham and Women's Hospital (related party transaction) indicate continued business relationships. The company's strategic objectives include menu expansion and new platform launches, which could benefit customers.
• Creditors: Financial performance, including net losses and cash usage, along with internal control weaknesses, could be a concern for creditors regarding the company's financial health and ability to meet obligations.
• Regulatory Authorities: The dismissal of EY and appointment of KPMG, along with the disclosure of material weaknesses and financial restatements, indicates ongoing engagement and potential scrutiny from the SEC and other regulatory bodies.

Next Steps

• Hold the 2025 Annual Meeting of Stockholders virtually on September 23, 2025.
• Stockholders to vote on director elections, executive compensation, auditor ratification, and proposed Charter amendments.
• If Proposal No. 4 (Board declassification) is approved, directors elected at the 2026 Annual Meeting and thereafter will serve one-year terms, with full declassification by the 2028 Annual Meeting.
• If Proposal No. 5 and/or No. 6 are approved, the Charter will be amended to eliminate supermajority voting requirements for certain Charter and Bylaw amendments.
• The company will appoint one new independent director by December 1, 2025, as per the Cooperation Agreement with Kent Lake Partners LP.
• The Board will adopt conforming changes to the Bylaws if the proposed Amended and Restated Charter is approved.
• The company will file a Current Report on Form 8-K within four business days of the Annual Meeting to disclose preliminary or final voting results.
• The Audit Committee will reconsider KPMG LLP's appointment if stockholders do not ratify it.
• The Compensation Committee and Board will review Say-on-Pay voting results and consider them for future executive compensation decisions.
• The next advisory vote on the frequency of the Say-on-Pay vote is expected at the 2028 Annual Meeting.

Key Dates

Recommendation

While Quanterix is taking positive steps in corporate governance by proposing board declassification and eliminating supermajority voting, and demonstrated strong relative revenue growth in 2024, the persistent net losses, significant decline in Total Shareholder Return, and unremediated material weaknesses in internal controls, including a recent financial restatement, present considerable risks. The discretionary adjustment of executive bonuses also warrants caution. The company is in a transitional phase, addressing past financial reporting issues and implementing governance changes. A 'hold' recommendation is appropriate as investors should monitor the effectiveness of these governance reforms, the remediation of internal control weaknesses, and the company's ability to translate relative revenue growth into sustained profitability before considering a more aggressive stance.

Keywords

Quanterix Corporation, SEC Filing, Proxy Statement, Corporate Governance, Board Declassification, Executive Compensation, Auditor Ratification, Financial Restatement, Material Weakness, Revenue Growth, Life Sciences Tools, Diagnostics, Biotechnology, Shareholder Vote, KPMG LLP, Ernst & Young LLP, SIMOA technology, Kent Lake Partners